Posted by Michael Wonder on 13 Nov 2016
Life-extending breast cancer drug approved by NICE in draft guidance
3 November 2016 - People with advanced breast cancer are set to benefit from a life-extending drug as NICE says it should be available on the NHS.
After considering new evidence that has become available since its 2012 guidance, NICE has said the drug should be an option for people with locally advanced breast cancer or breast cancer that has spread despite them having had at least 2 prior chemotherapy treatments.
Eribulin mesylate is recommended only if the company provides it with the discount agreed in the patient access scheme.
